Free Trial
NASDAQ:JSPR

Jasper Therapeutics Q3 2024 Earnings Report

Jasper Therapeutics logo
$3.42 -0.09 (-2.42%)
As of 09:47 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Jasper Therapeutics EPS Results

Actual EPS
-$1.24
Consensus EPS
-$1.09
Beat/Miss
Missed by -$0.15
One Year Ago EPS
N/A

Jasper Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Jasper Therapeutics Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
7:30AM ET

Upcoming Earnings

Jasper Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Monday, August 11, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Jasper Therapeutics Earnings Headlines

Critical Minerals Are Taking Center Stage in This Administration
With growing global demand and new federal initiatives, critical minerals are now a top national priority. There is little known company on the OTC that can reap the benefits of these fast moving legislations. While its sister already trades on the NASDAQ, this stock could be headed for Monumental growth if it follows in its sibling's footsteps… Sign up now to get instant access to the report that could reshape the way you look at mining stocks.. Time is of the essence traders…
William Blair Analysts Raise Earnings Estimates for JSPR
See More Jasper Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jasper Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jasper Therapeutics and other key companies, straight to your email.

About Jasper Therapeutics

Jasper Therapeutics (NASDAQ:JSPR) is a clinical-stage biotechnology company dedicated to discovering and developing novel therapies that target the complement system for the prevention and treatment of rare diseases, organ transplant rejection and certain inflammatory conditions. Its lead product candidate, nomacopan, is an investigational, small‐protein dual inhibitor of complement component C5 and leukotriene B4, designed to address the underlying drivers of tissue damage in disorders such as paroxysmal nocturnal hemoglobinuria (PNH), bullous pemphigoid and cutaneous acute graft-versus-host disease. In addition to nomacopan, Jasper’s pipeline includes earlier-stage complement inhibitors aimed at improving transplant outcomes in kidney and other solid-organ recipients.

Founded in 2015 as a spin-out from the University of Pennsylvania and the University of Washington, Jasper Therapeutics completed its initial public offering on the Nasdaq in 2018. The company has established strategic collaborations and license agreements to support global development and commercialization, leveraging partnerships with leading pharmaceutical firms to expand the reach of its complement‐modulating technology. Headquartered in Plymouth, Minnesota, Jasper conducts multi‐center clinical trials across North America, Europe and Australia.

Jasper’s management team brings deep expertise in immunology, rare disease development and regulatory strategy. The company is led by a seasoned executive team and board of directors with decades of experience guiding small and mid‐sized biopharmaceutical enterprises through late‐stage clinical trials and toward potential commercialization. This leadership collective underscores Jasper’s commitment to advancing its pipeline and delivering transformative therapies for patients with high‐unmet medical needs.

View Jasper Therapeutics Profile

More Earnings Resources from MarketBeat